BASKING RIDGE, N.J., March 9, 2006 (PRIMEZONE) -- VioQuest Pharmaceuticals, Inc. (OTCBB:VQPH), a New Jersey-based biopharmaceutical company focused on acquiring, developing and commercializing targeted cancer compounds, will present a corporate overview at the Sachs North America Forum for Investing and Partnering in Biotech and Medtech on Monday, March 13, at 12:25 p.m. (EST). The event, which is expected to draw over 500 delegates from the USA and overseas representing both listed and private biotech companies, will be held at The Fairmont Copley Plaza from March 13 thru 14, 2006.
Daniel Greenleaf, President and CEO of VioQuest, will provide a comprehensive company overview including an update on recent corporate and scientific developments.
Additional information regarding the conference can be found at www.sachsforum.com.
About VioQuest Pharmaceuticals, Inc.
VioQuest Pharmaceuticals, Inc. acquires, develops and commercializes targeted late preclinical and early clinical stage therapies with unique mechanisms of action for oncology, viral and autoimmune disorders. A leader in personalized therapeutics, VioQuest has two targeted therapeutics in clinic trials: VQD-001, an inhibitor of specific protein tyrosine phosphatases, has shown compelling preclinical activity in both renal and melanoma cancers, and VQD-002, which has been shown to inhibit the phosphorylation of Akt seen in abnormal levels in breast, ovarian, colorectal, pancreatic and liquid cancers.
VioQuest subsidiary Chiral Quest, a pioneer in asymmetric chemocatalysis and custom synthesis, offers its proprietary technology products to well-known pharmaceutical and fine chemical companies worldwide to improve their production efficiencies and, in some instances, to increase the overall safety and efficacy of the underlying drug. For more information please visit www.vioquestpharm.com.
Forward-Looking Statements: This press release contains forward-looking statements that involve risks and uncertainties that could cause VioQuest's actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of VioQuest's research programs and compounds will be successfully commercialized. Risks, uncertainties and assumptions also include the possibility that the market for the sale of certain products may not develop as expected; and that development of these products may not proceed as planned. Additional risks are described in VioQuest's Annual Report on Form 10-KSB for the year ended December 31, 2004. VioQuest assumes no obligation and does not intend to update these forward-looking statements, except as required by law.